Additional file 1: of Sub-analysis of geographical variations in the 2-year observational COPTIMIZE trial of patients with relapsing–remitting multiple sclerosis converting to glatiramer acetate

Patient perception of glatiramer acetate treatment efficacy by geographic region. aP < .0001 for Latin America vs. other geographic areas. (PDF 7 kb